2025 年干眼症治疗药物 品牌推荐 市场规模·····十大品牌·排行榜 | 一、市场背景 2 | | --- | | 1.1 摘要 2 | | 1.2 干眼症定义 2 | | 1.3 市场演变 2 | | 二、市场现状 3 | | 2.1 市场规模 3 | | 2.2 市场供需 3 | | 三、市场竞争 4 | | 3.1 市场评估维度 4 | | 3.2 市场竞争格局 4 | | 3.3 十大品牌推荐 4 | | 四、发展趋势 6 | | 4.1 市场规模持续增长 6 | | 4.2 药物创新多元化发展 7 | | 4.3 本土企业崛起与全球化布局 7 | | 4.4 竞争格局与风险应对 7 | 2025 年干眼症治疗药物品牌推荐 一、市场背景 1.1 摘要 随着公众对视觉健康关注度的提升，干眼症已从职场及老年群体的"专属困扰"，演变为 覆盖全年龄段的慢性眼部健康挑战。2024 年中国干眼症患病人数已达 3.6 亿，但治疗率 仅 10%-12%，市场潜力巨大。制剂技术与给药系统革新推动药物从传统人工泪液向多剂 量无防腐剂制剂、新型递药途径升级，以环孢素滴眼液、全氟己基辛烷眼用制剂等为代 表的新机制疗法成为 ...

Core Viewpoint - The FDA has granted Fast Track Designation (FTD) to Irpagratinib (ABSK-011), a selective FGFR4 inhibitor developed by the company, for the treatment of advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have previously received immune checkpoint inhibitors (ICI) and multi-target kinase inhibitors (mTKI) [1][4]. Group 1: FDA Fast Track Designation - The Fast Track Designation aims to expedite the development and review process of innovative therapies for serious diseases with unmet clinical needs, allowing for earlier and more frequent communication with the FDA [3]. - The designation will accelerate global clinical development and registration processes for Irpagratinib, potentially shortening the time to market [3]. Group 2: Clinical Data and Efficacy - In a Phase I clinical study presented at the 2024 ESMO annual meeting, Irpagratinib demonstrated an objective response rate (ORR) of 46.7% and a median progression-free survival (mPFS) of 5.5 months in HCC patients with FGF19 overexpression who had progressed after ICI and mTKI treatments [4]. - The safety and tolerability profile of Irpagratinib was reported to be favorable [4]. Group 3: Combination Therapy Exploration - The company is also exploring combination therapy with Irpagratinib and Roche's PD-L1 inhibitor Atezolizumab, which has shown an ORR exceeding 50% and mPFS over 7 months in both treatment-naive and previously treated FGF19 overexpressing HCC patients, with no new safety signals observed [4]. - The results suggest a potential synergistic mechanism between FGFR4 inhibitors and ICIs, aligning with accumulating preclinical and translational research evidence [4]. Group 4: Precision Oncology Shift - Irpagratinib represents a significant shift towards precision oncology in the treatment of liver cancer, moving away from relatively non-selective systemic therapies [5]. - The development path of Irpagratinib aligns closely with the global trend towards molecularly driven precision therapies, aiming to establish a new treatment paradigm for patients with FGF19 overexpression [5].

Core Insights - Evaluate's latest report indicates that ten innovative therapies are expected to receive FDA approval in 2026, covering various fields such as metabolic diseases, oncology, and autoimmune conditions, signaling a shift in treatment paradigms for the coming years [1] Metabolic Diseases - The competition between Novo Nordisk and Eli Lilly in the obesity treatment market is intensifying with the upcoming submissions of CagriSema and Orforglipron, which may reshape the treatment landscape for obesity [5] - CagriSema is a fixed-dose combination therapy of cagrilintide and semaglutide, designed for weekly subcutaneous injection, aiming to effectively regulate metabolism and achieve weight loss through multiple mechanisms [5][6] - Orforglipron is an oral GLP-1 receptor agonist that can be taken at any time of the day, enhancing patient compliance due to its convenient dosing regimen [6] - Clinical trials show that CagriSema achieved a weight loss of 20.4% at week 68 compared to 3.0% in the placebo group, while Orforglipron also demonstrated significant weight loss and improvements in metabolic risk factors [7][8] - Both drugs represent trends in obesity treatment: combination therapy and oral GLP-1 agonists, potentially leading to a more competitive market and increased R&D investments in metabolic disease therapies [9] Cell Therapy - Anitocabtagene autoleucel (anito-cel), a CAR-T therapy targeting BCMA, is expected to provide breakthroughs in treating multiple myeloma, addressing challenges in expanding CAR-T therapy to solid tumors [10] - The innovative D-Domain design of anito-cel improves CAR expression stability and reduces immune-related adverse effects, enhancing its therapeutic efficacy [11] - Clinical data shows a total response rate of 96% and a 24-month overall survival rate of 83% for patients treated with anito-cel, indicating its potential as a durable treatment option [12] Autoimmune Diseases - Brepocitinib and Icotrokinra are poised to optimize precision treatment strategies in autoimmune diseases, moving from broad-spectrum immunosuppression to targeted mechanisms [14] - Brepocitinib is a selective TYK2/JAK1 inhibitor that effectively blocks pathogenic signaling pathways without broadly suppressing normal immune function, showing significant clinical improvement in dermatomyositis patients [15] - Icotrokinra is a first-in-class oral therapy targeting IL-23R, demonstrating significant efficacy in treating moderate to severe plaque psoriasis [16][17] - Both therapies utilize oral administration, enhancing patient compliance and potentially transforming treatment paradigms in autoimmune diseases [19] Breast Cancer Treatment - Gedatolisib, a multi-target PAM inhibitor, aims to address resistance issues in HR+/HER2- advanced breast cancer by fully blocking the PAM pathway [20] - Clinical trials indicate that gedatolisib significantly improves progression-free survival (PFS) in patients with HR-positive, HER2-negative advanced breast cancer [21][22] - Camizestrant, a new oral selective estrogen receptor degrader (SERD), shows promise in treating patients with ESR1 mutations, enhancing treatment efficacy [23][24] - The combination of gedatolisib and camizestrant represents a shift towards multi-pathway combination therapies, providing new treatment avenues for resistant breast cancer patients [26][27] Rare Diseases - Baxdrostat, Ulixacaltamide, and Atacicept are innovative therapies targeting unmet needs in hypertension, essential tremor, and IgA nephropathy, respectively, showcasing the industry's focus on rare diseases [28][35] - Baxdrostat is a selective oral aldosterone synthase inhibitor that has shown significant efficacy in treating resistant hypertension [29][30] - Ulixacaltamide is a selective T-type calcium channel inhibitor that has demonstrated efficacy in treating essential tremor [31][32] - Atacicept targets B-cell activation factors, showing promise in reducing proteinuria in IgA nephropathy patients [33][34] Conclusion - The ten therapies highlighted reflect a shift towards precision medicine, optimized delivery strategies, and improved clinical response rates, marking a transition in biopharmaceutical development towards patient-centered and data-driven decision-making [36]

Core Insights - Cancer prevention and control is a critical issue for public health in China, requiring collaborative efforts to address health needs and challenges [2][3][9] Group 1: Cancer Treatment Innovations - The treatment of liver and biliary tumors has entered an immunotherapy-dominated phase, significantly extending patient survival and creating curative opportunities for inoperable tumors [2] - Advances in lung cancer treatment, including new T-cell antibody drugs and combination therapies, have improved survival rates and quality of life for patients [4] - The development of innovative therapies in gastrointestinal tumors, such as targeted therapies for esophageal and gastric cancers, has led to significant clinical breakthroughs [4][6] Group 2: Multidisciplinary Collaboration - A multidisciplinary approach is becoming the mainstream trend in cancer treatment, allowing for personalized treatment plans that consider the overall health of patients [3][8] - Enhancing the capabilities of grassroots medical institutions is essential for improving cancer prevention and control systems [3][8] Group 3: Systematic Improvements - A robust diagnostic and treatment system, along with a well-trained talent pool, is fundamental for long-term cancer prevention efforts [7] - The integration of innovative therapies and standardized treatment protocols is necessary to address the challenges faced in gastrointestinal cancer treatment [6][7] Group 4: Future Directions - Continuous clinical research and innovation are vital for accelerating the development and application of new treatment technologies [3][4][9] - The "People's Good Doctor · Camellia Plan" aims to promote clinical research and the training of young medical professionals in oncology, enhancing the overall capacity for cancer prevention and control [9]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]

Core Insights - The National High-Performance Medical Device Innovation Center released the "2025 Medical Device Industry Innovation Ecosystem Insights" list, highlighting emerging companies, institutions, individuals, and products in China's medical device industry [1] - The assessment covers the entire chain from technology research and development to market application, showcasing the innovative ecosystem of China's medical device industry for 2025 [1] Group 1: Assessment Framework - The evaluation system has evolved from a dual dimension of "companies + individuals" to a comprehensive framework covering seven dimensions, including companies, individuals, products, universities, hospitals, investment institutions, and industrial parks [2] - This comprehensive assessment network achieves full coverage of the innovation chain, industrial chain, and capital chain [2] Group 2: Achievements and Innovations - Over the past five years, the center has made significant breakthroughs in key technologies, including the world's first 5.0T whole-body MRI and the first domestic ECMO, positioning these innovations among the international top tier [2] - The center has completed the domestic manufacturing of ECMO within three years, achieving performance metrics on par with international counterparts, marking a significant milestone in the development of high-end medical equipment in China [2] Group 3: Technological Advancements - The center is focused on strengthening core components and key raw materials, achieving full-chain domestic production for high-performance AFE chips and high-precision medical nickel-titanium materials [3] - In the past five years, the center has undertaken over 120 national and local research tasks, filed 296 patents (with two-thirds being invention patents), and participated in the revision of 11 industry standards [3] Group 4: Strategic Contributions - The center has played a pivotal role in strategic research and planning, contributing to over 30 strategic studies and deeply engaging in the national high-end medical equipment "14th Five-Year" top-level strategic planning [3] - It provides substantial intellectual support for national strategies, government decision-making, industrial resource collaboration, and corporate strategic layout [3]

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The report highlights the ongoing transformation in cancer treatment, moving from broad-spectrum therapies to precision medicine, with a focus on innovative technologies such as bispecific antibodies, antibody-drug conjugates (ADC), and CAR-T therapies [7][14] - It emphasizes the importance of companies with cutting-edge technology platforms and differentiated research strategies, particularly in the context of blood cancers becoming manageable chronic diseases [11][14] - The report suggests that the recent ESMO Asia and ASH conferences have positively influenced market sentiment, revealing clear directions for future cancer treatments [11][14] Summary by Sections Industry Overview - The pharmaceutical sector is experiencing significant internal differentiation, with some sub-sectors like pharmaceutical commerce and traditional Chinese medicine performing well, while others like medical devices and chemical pharmaceuticals are facing declines [7][11] - The total market capitalization of the industry is approximately 72,066.76 billion [2] Key Investment Directions - Focus on biotech companies with innovative technology platforms, particularly those developing new delivery systems and ADCs targeting specific cancer markers [11][14] - Look for companies implementing differentiated research strategies, especially in rare target areas and combination therapies [11][14] - Recognize the long-term investment value in blood cancers as they transition into manageable chronic conditions, expanding the market for existing and new therapies [11][14] Market Dynamics - The report notes that the pharmaceutical sector's performance has been mixed, with a year-to-date return of 15.86%, slightly lagging behind the broader market [11] - The report identifies key companies to watch, including 康方生物, 药明合联, and others, which are expected to perform well based on their innovative approaches and market positioning [8][11][14]

Core Viewpoint - The announcement by Innovent Biologics regarding the successful completion of the GLORY-2 Phase III clinical trial for its GCG/GLP-1 dual receptor agonist, Ma Shidu, provides a new non-invasive weight loss option for the significant population of obese individuals in China, showing efficacy comparable to weight loss surgery [1][2][3] Group 1: Clinical Trial Results - The GLORY-2 trial achieved its primary endpoint and all key secondary endpoints, demonstrating significant weight loss in participants with a baseline BMI over 34 kg/m², with an average weight reduction of 20.08% compared to placebo [1][2] - The study included 462 participants, with a 2:1 random allocation to the Ma Shidu 9 mg group or placebo, and a treatment duration of 60 weeks [2] - Improvements were noted in various metabolic indicators, including waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels, with good tolerability and safety [1][2][3] Group 2: Market Implications - The high obesity prevalence in China, particularly among individuals with a BMI over 30 kg/m², highlights the need for effective non-invasive treatment options for this patient group, which currently relies heavily on metabolic surgery [1][2] - The successful results of the GLORY-2 trial position Ma Shidu as a promising new treatment option for managing obesity and related metabolic syndromes, potentially transforming the treatment landscape for this demographic [2][3] - Innovent Biologics plans to submit a marketing application for Ma Shidu 9 mg to the National Medical Products Administration (NMPA) to expedite access to this treatment for the Chinese population [3]

Core Insights - Recent clinical achievements in the innovative pipeline of YuanDa Pharmaceutical (00512) enhance its competitive edge in the nuclear medicine oncology diagnosis and treatment sector with the completion of patient enrollment for the GPN00289 clinical study [1] - The aXess product, a groundbreaking artificial blood vessel, has shown unprecedented safety and efficacy in key clinical trials, potentially revolutionizing treatment for end-stage renal disease (ESRD) patients [1][7] Group 1: Clinical Developments - The aXess product has demonstrated superior patency rates and lower re-intervention rates compared to traditional arteriovenous fistulas (AVF), addressing significant clinical challenges faced by ESRD patients [7] - In a prospective study involving 120 patients, only one case of infection-related removal of the artificial vessel was reported, highlighting the product's high anti-infection performance [7] - The aXess product utilizes endogenous tissue repair (ETR) technology, allowing for rapid integration with the patient's own tissue, thus reducing complications associated with traditional dialysis access methods [8] Group 2: Market Potential - Chronic kidney disease (CKD) poses a significant global health challenge, with approximately 850 million affected individuals, and ESRD cases expected to rise to nearly 14.61 million by 2030, growing at a compound annual growth rate (CAGR) of about 4.5% [2] - In China, ESRD patients account for over 30% of the global total, with projections indicating that the number will exceed 6.2 million by 2030 [2] - The blood purification market in China is projected to grow significantly, with a CAGR of approximately 6.5% from 2019 to 2022, potentially reaching nearly 48.4 billion RMB by 2030 [5] Group 3: Product Synergy and Strategic Expansion - The aXess product is part of a broader strategy in YuanDa's cardiovascular precision intervention platform, which includes over 30 high-end medical device products, with 22 already approved in China [9] - The company aims to leverage the aXess product alongside another innovative device, APERTO OTW, to enhance dialysis access pathways for patients [9] - YuanDa is actively pursuing international collaborations and has established partnerships with clinical centers and research platforms in multiple countries, supporting its "Go Global" strategy [11]

Core Insights - Recent clinical achievements in the innovative pipeline of YuanDa Pharmaceutical (00512) enhance its competitive edge in the nuclear medicine oncology diagnosis and treatment sector, particularly with the completion of patient enrollment for the GPN00289 temperature-sensitive embolization agent [1] - The aXess product, a groundbreaking artificial blood vessel, has shown unprecedented safety and efficacy in key clinical trials, indicating a potential shift in treatment paradigms for end-stage renal disease (ESRD) patients [1][10] Group 1: Clinical Developments - The aXess product has successfully completed pivotal clinical trials in Europe, demonstrating superior patency rates and lower re-intervention rates compared to existing arteriovenous fistula (AVF) methods [9] - The clinical trial involved 120 patients, with only one case of infection-related removal of the artificial vessel, highlighting its high anti-infection performance [9] - aXess utilizes unique endogenous tissue repair technology, allowing for rapid integration with the patient's own tissue, which may significantly reduce complications associated with traditional dialysis access methods [10] Group 2: Market Context - Chronic kidney disease (CKD) poses a significant global health challenge, with approximately 850 million affected individuals, and ESRD cases expected to rise to nearly 14.61 million by 2030, reflecting a compound annual growth rate of about 4.5% [2] - In China, ESRD patients account for over 30% of the global total, with projections indicating that numbers will exceed 6.2 million by 2030 [2] Group 3: Product Synergy and Strategic Positioning - The aXess product is part of a broader strategy in YuanDa's cardiovascular precision intervention platform, which includes over 30 high-end medical device products, with 22 already approved for market in China [11][14] - The company aims to leverage the synergy between aXess and another innovative device, APERTO® OTW, to enhance dialysis access for patients [11] - YuanDa's commitment to innovation is reflected in its ongoing development of multiple products, with a focus on meeting clinical needs and expanding its international presence through strategic partnerships [15]